tetano
Editor, Senior Moderator
Reumatol Clin
. 2020 Sep 11;S1699-258X(20)30201-1.
doi: 10.1016/j.reuma.2020.08.004. Online ahead of print.
SARS-CoV-2 (COVID-19) in Patients with some Degree of Immunosuppression
[Article in En, Spanish]
Jairo Cajamarca-Baron[SUP] 1 [/SUP], Diana Guavita-Navarro[SUP] 2 [/SUP], Jhon Buitrago-Bohorquez[SUP] 2 [/SUP], Laura Gallego-Cardona[SUP] 2 [/SUP], Angela Navas[SUP] 3 [/SUP], Hector Cubides[SUP] 4 [/SUP], Ana Mar?a Arredondo[SUP] 4 [/SUP], Alejandro Escobar[SUP] 4 [/SUP], Adriana Rojas-Villarraga[SUP] 5 [/SUP]
Affiliations
Abstract
Background: It is not clear whether patients with some degree of immunosuppression have worse outcomes in SARS-CoV-2 infection, compared to healthy people.
Objective: To carry out a narrative review of the information available on infection by SARS-CoV-2 in immunosuppressed patients, especially patients with cancer, transplanted, neurological diseases, primary and secondary immunodeficiencies.
Results: Patients with cancer and recent cancer treatment (chemotherapy or surgery) and SARS-CoV-2 infection have a higher risk of worse outcomes. In transplant patients (renal, cardiac and hepatic), with neurological pathologies (multiple sclerosis [MS], neuromyelitis optica [NMODS], myasthenia gravis [MG]), primary immunodeficiencies and infection with human immunodeficiency virus (HIV) in association with immunosuppressants, studies have shown no tendency for worse outcomes.
Conclusion: Given the little evidence we have so far, the behaviour of SARS-CoV-2 infection in immunosuppressed patients is unclear, but current studies have not shown worse outcomes, except for patients with cancer.
Keywords: Cancer; Coronavirus; C?ncer; Diseases of the nervous system; Enfermedades del sistema nervioso; Enfermedades reum?ticas; Human immunodeficiency virus; Immunosuppression; Inmunosupresi?n; Rheumatic diseases; Transplantation; Trasplante; Virus de la inmunodeficiencia humana.
. 2020 Sep 11;S1699-258X(20)30201-1.
doi: 10.1016/j.reuma.2020.08.004. Online ahead of print.
SARS-CoV-2 (COVID-19) in Patients with some Degree of Immunosuppression
[Article in En, Spanish]
Jairo Cajamarca-Baron[SUP] 1 [/SUP], Diana Guavita-Navarro[SUP] 2 [/SUP], Jhon Buitrago-Bohorquez[SUP] 2 [/SUP], Laura Gallego-Cardona[SUP] 2 [/SUP], Angela Navas[SUP] 3 [/SUP], Hector Cubides[SUP] 4 [/SUP], Ana Mar?a Arredondo[SUP] 4 [/SUP], Alejandro Escobar[SUP] 4 [/SUP], Adriana Rojas-Villarraga[SUP] 5 [/SUP]
Affiliations
- PMID: 32994151
- DOI: 10.1016/j.reuma.2020.08.004
Abstract
Background: It is not clear whether patients with some degree of immunosuppression have worse outcomes in SARS-CoV-2 infection, compared to healthy people.
Objective: To carry out a narrative review of the information available on infection by SARS-CoV-2 in immunosuppressed patients, especially patients with cancer, transplanted, neurological diseases, primary and secondary immunodeficiencies.
Results: Patients with cancer and recent cancer treatment (chemotherapy or surgery) and SARS-CoV-2 infection have a higher risk of worse outcomes. In transplant patients (renal, cardiac and hepatic), with neurological pathologies (multiple sclerosis [MS], neuromyelitis optica [NMODS], myasthenia gravis [MG]), primary immunodeficiencies and infection with human immunodeficiency virus (HIV) in association with immunosuppressants, studies have shown no tendency for worse outcomes.
Conclusion: Given the little evidence we have so far, the behaviour of SARS-CoV-2 infection in immunosuppressed patients is unclear, but current studies have not shown worse outcomes, except for patients with cancer.
Keywords: Cancer; Coronavirus; C?ncer; Diseases of the nervous system; Enfermedades del sistema nervioso; Enfermedades reum?ticas; Human immunodeficiency virus; Immunosuppression; Inmunosupresi?n; Rheumatic diseases; Transplantation; Trasplante; Virus de la inmunodeficiencia humana.